Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk announces acquisitions of Calibrium and MB2

Novo Nordisk announces acquisitions of Calibrium and MB2

28th August 2015

Novo Nordisk has announced the purchase of the biopharmaceutical research companies Calibrium and MB2 as it seeks to bolster its diabetes and obesity capabilities.

Formed in 2013 and 2014, respectively, the Indiana-based companies are focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases.

The acquisition will expand Novo Nordisk's portfolio of projects and intellectual property rights within diabetes and obesity, while providing a basis for expanding the company's research presence in the US.

It is expected that the closure of the deal, which is subject to US regulatory approval, will occur during the third quarter of 2015.

Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said: "This research team has demonstrated world-class capabilities in protein design and created a project portfolio of innovative product leads that fits very well with our aspirations within diabetes and obesity."

The company experienced strong double-digit growth during the first six months of 2015, thanks to demand for products such as Victoza and Levemir.ADNFCR-8000103-ID-801799045-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.